ARVEE LABORATORIES (INDIA) LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 193 INR | +1.61% |
|
+4.44% | +11.62% |
| 17/05 | Arvee Laboratories Ltd. Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 | CI |
| 26/03 | Arvee Laboratories Ltd. Announces Resignation of Mr. Dipen Dalal as Independent Director | CI |
| Sales 2022 | 403M 4.85M | Sales 2023 | 613M 7.38M | Capitalization | 970M 11.67M |
|---|---|---|---|---|---|
| Net income 2022 | 25M 301K | Net income 2023 | 41M 493K | EV / Sales 2022 | 3.07 x |
| Net cash position 2022 | 14.98M 180K | Net Debt 2023 | 1.08M 13.03K | EV / Sales 2023 | 1.58 x |
| P/E ratio 2022 |
48.7
x | P/E ratio 2023 |
23.5
x | Employees | 67 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.61% | ||
| 1 week | +4.44% | ||
| 1 month | -9.43% | ||
| 3 months | +46.14% | ||
| 6 months | +43.05% | ||
| Current year | +11.62% |
1 week
181.60
203.45
1 month
179.15218.05
Current year
117.05315.00
1 year
98.10315.00
3 years
62.90315.00
5 years
18.80315.00
10 years
18.80315.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 01/14/01 | |
| Director of Finance/CFO | - | 10/18/10 | |
| Compliance Officer | 33 | 15/19/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 36 | 01/21/01 | |
| Chief Executive Officer | 50 | 01/14/01 | |
| Director/Board Member | 39 | 27/12/27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 193 | +1.61% | 621 |
| 30/24/30 | 190 | -3.99% | 1,053 |
| 29/24/29 | 197.9 | +2.51% | 1,095 |
| 28/24/28 | 193 | -0.39% | 2,469 |
| 27/24/27 | 193.8 | +4.84% | 5,125 |
Delayed Quote NSE India S.E., May 31, 2024 at 05:13 pm IST
More quotes
Arvee Laboratories (India) Limited is an India-based company engaged in manufacturing of specialized chemicals. The Company's product categories include polymer modifiers, contrast media intermediates and drug intermediates. Its polymer modifiers products include Dimethyl 5-Sodiosulfoisophthalate, 5-Sulfoisophthalic Acid Mono Sodium Salt, 5-Sulfoisophthalic Acid Mono Lithium Salt and 5-Sodiosulfo-Bis-(B-Hydroxyethyl)-Isophthalate. The Company's contrast media intermediates products include 5-Nitroisophthalic acid, Dimethyl 5-Nitroisophthalate, Monomethyl 5-Nitroisophthalate, 5-Hydroxyisophthalic acid, 5-Aminoisophthalic acid, Dimethyl 5-Aminoisophthalate, and 3,5-Diamino Benzoic Acid. Its drug intermediates products include 2-Acetyl Thiophene, Thiophene-2-Carboxaldehyde, 4-Amino Pyridine and 2-Chloro-5-Nitrobenzoic Acid.
Sector
Diversified Chemicals
Calendar
30/07/2024
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +11.62% | 25.49M | |
| +0.56% | 74.34B | |
| -0.76% | 46.86B | |
| +6.80% | 34.35B | |
| +9.37% | 18.1B | |
| +12.81% | 11.92B | |
| -3.01% | 10.43B | |
| -20.72% | 10.33B | |
| -0.24% | 9.04B | |
| -9.95% | 7.84B |
- Stock Market
- Equities
- ARVEE Stock
